ArticleLeukemia2026

Direct measurement of in vivo BCR::ABL1 kinase inhibition reveals stronger potency of asciminib as compared with imatinib and nilotinib.

Chung Hoow Kok et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.